Abstract
NSCLC, NCT03358875, lung cancer
LUNG CANCER, NSCLC
This study examined the health‐related quality of life (HRQoL) of patients with advanced non‐small cell lung cancer (NSCLC) receiving tislelizumab versus docetaxel in the open‐label, multicenter, Phase 3 trial called RATIONALE‐303 (NCT03358875). HRQoL was assessed with the EORTC QLQ‐C30, EORTC QLQ‐LC13, and the EQ‐5D‐5L instruments. A longitudinal analysis of covariance assessed the change from baseline to Week 12 and from baseline to Week 18. A time to deterioration analysis was also performed using the Kaplan–Meier method. Eight hundred and five patients were randomized to either tislelizumab (Patients with advanced non‐small cell lung cancer (NSCLC) have a poor prognosis and poor health‐related quality of life (HRQoL). This study found that patients treated with tislelizumab had greater improvements in the HRQoL measures of the EORTC QLQ‐C30 and EORTC lung cancer module (QLQ‐LC13) scales and scores compared with patients treated with docetaxel. These results support the favorable risk‐benefit ratio of tislelizumab as a second‐line therapy in patients with NSCLC who previously failed treatment with a platinum‐containing chemotherapy.
Clinical Trial Number: NCT03358875.